• Explore /
  • Poster
  • / A prospective study of FOLFIRI plus aflibercept as second-line treatment after failure of FOLFOXIRI plus bevacizumab in patients with unresectable/metastatic colorectal cancer (CRC): EFFORT study.

A prospective study of FOLFIRI plus aflibercept as second-line treatment after failure of FOLFOXIRI plus bevacizumab in patients with unresectable/metastatic colorectal cancer (CRC): EFFORT study.

Abstract Poster

Authors

null

Hironaga Satake

Department of Medical Oncology, Kochi Medical School, Nankoku-City, Japan

Hironaga Satake , Koji Ando , Hisateru Yasui , Yuji Negoro , Tatsuya Kinjo , Koutarou Yuge , Kenji Baba , Hiroyuki Orita , Keiji Hirata , Mototsugu Shimokawa , Akitaka Makiyama , Hiroshi Saeki , Eiji Oki , Hideo Baba

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

jRCTs071190003

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3549)

DOI

10.1200/JCO.2023.41.16_suppl.3549

Abstract #

3549

Poster Bd #

249

Abstract Disclosures

Similar Posters

First Author: Federica Marmorino

First Author: Benoist Chibaudel

First Author: Sebastian Stintzing

First Author: Zhichao Jiang